

Azmil H Abdul-Rahim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3026543/publications.pdf>

Version: 2024-02-01

142
papers

42,497
citations

36303

51
h-index

9589

142
g-index

142
all docs

142
docs citations

142
times ranked

35691
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	27.0	7,537
2	2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
3	Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004.	27.0	5,052
4	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	27.0	2,491
5	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
6	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	27.0	2,240
7	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.	13.7	1,752
8	Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine, 2020, 382, 1653-1659.	27.0	1,732
9	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, The, 2003, 362, 772-776.	13.7	1,623
10	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395.	13.7	990
11	Obesity Is a Risk Factor for Severe COVID-19 Infection. Circulation, 2020, 142, 4-6.	1.6	595
12	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
13	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 1377-1385.	2.2	549
14	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
15	Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. Circulation, 2009, 119, 515-523.	1.6	468
16	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
17	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
18	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 2009, 11, 170-177.	7.1	326

#	ARTICLE	IF	CITATIONS
19	Heart failure with midâ€range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	7.1	295
20	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
21	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2175-2182.	2.0	213
22	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
23	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.	2.2	184
24	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the â€œPRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	7.1	183
25	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
26	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
27	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.	2.7	141
28	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011, 32, 1227-1234.	2.2	130
29	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€CHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	7.1	129
30	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	3.9	123
31	Lung Ultrasound in Acute Heartâ€Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.	4.1	116
32	Clinical Selection Strategies to Identify Ischemic Stroke Patients With Large Anterior Vessel Occlusion. <i>Stroke</i> , 2017, 48, 290-297.	2.0	115
33	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	2.2	114
34	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	93
35	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 1486-1494.	1.6	92
36	Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry. <i>BMC Neurology</i> , 2014, 14, 198.	1.8	91

#	ARTICLE	IF	CITATIONS
37	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 844-851.	7.1	91
38	Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms. <i>Circulation</i> , 2012, 126, 2317-2323.	1.6	90
39	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	89
40	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants (RAVENOACs) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	89
41	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021, 23, 703-712.	7.1	87
42	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
43	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. <i>European Journal of Heart Failure</i> , 2010, 12, 17-24.	7.1	84
44	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Tj ETQq0 0 0 rgBT /Overlock 10 Therapy. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	83
45	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	4.4	83
46	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1149-1151.	3.6	83
47	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	3.9	80
48	Urate, Blood Pressure, and Cardiovascular Disease. <i>Hypertension</i> , 2021, 77, 383-392.	2.7	75
49	“Hearts and minds”: association, causation and implication of cognitive impairment in heart failure. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 22.	6.2	73
50	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 607-616.	7.1	71
51	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019, 50, 2168-2174.	2.0	59
52	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	3.9	55
53	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018, 7, e010133.	3.7	55
54	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	53

#	ARTICLE	IF	CITATIONS
55	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	7.1	52
56	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	52
57	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	7.1	52
58	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019, 42, 1792-1799.	8.6	52
59	Return to the Workforce After First Hospitalization for Heart Failure. <i>Circulation</i> , 2016, 134, 999-1009.	1.6	50
60	How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 783-790.	2.2	48
61	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <sc>MAGGIC</sc> meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	7.1	48
62	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALSartan in acute myocardial infarction trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.	2.2	47
63	Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013306.	2.8	47
64	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	8.6	47
65	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1139-1145.	7.1	45
66	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018, 20, 268-277.	7.1	42
67	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021, 144, 199-209.	1.6	40
68	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 506-522.	2.4	39
69	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	7.1	37
70	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	2.2	36
71	The Incidence and Associated Factors of Early Neurological Deterioration After Thrombolysis. <i>Stroke</i> , 2020, 51, 2705-2714.	2.0	33
72	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016, 263, 231-237.	3.6	32

#	ARTICLE	IF	CITATIONS
73	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. <i>Stroke</i> , 2017, 48, 726-732.	2.0	32
74	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	2.7	32
75	Rationale for and design of the <sc>TRUEâ€œAHF</sc> trial: the effects of ularitide on the shortâ€œterm clinical course and longâ€œterm mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	7.1	31
76	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensinâ€œconverting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€œAdded trial. <i>European Journal of Heart Failure</i> , 2008, 10, 157-163.	7.1	30
77	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. <i>Stroke</i> , 2015, 46, 395-400.	2.0	30
78	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019, 50, 2093-2100.	2.0	29
79	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 727-735.	2.8	28
80	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. <i>Stroke</i> , 2022, 53, 2620-2627.	2.0	28
81	Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. <i>Circulation: Heart Failure</i> , 2013, 6, 203-210.	3.9	26
82	Statins and risk of poststroke hemorrhagic complications. <i>Neurology</i> , 2016, 86, 1590-1596.	1.1	26
83	Practical â€œ1-2-3-4-Dayâ€œRule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. <i>Stroke</i> , 2022, 53, 1540-1549.	2.0	26
84	Derivation and Validation of a Novel Prognostic Scale (Modifiedâ€œStroke Subtype, Oxfordshire) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Mortality in Acute Stroke. <i>Stroke</i> , 2016, 47, 74-79.	2.0	25
85	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021, 44, 1877-1884.	8.6	25
86	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (REDâ€œHF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	7.1	24
87	Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. <i>Heart</i> , 2014, 100, 557-562.	2.9	24
88	Biomarkers for Atrial Fibrillation Detection After Stroke. <i>Neurology</i> , 2021, 97, e1775-e1789.	1.1	23
89	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016, 209, 310-316.	1.7	22
90	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heartâ€œFailure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 683-698.	2.8	22

#	ARTICLE	IF	CITATIONS
91	Sex and Stroke in Thrombolized Patients and Controls. Stroke, 2017, 48, 367-374.	2.0	21
92	Barcelona Bioâ€HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. European Journal of Heart Failure, 2018, 20, 938-940.	7.1	20
93	Systolic blood pressure reduction during the first 24â€h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322.	7.1	20
94	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031.	7.1	20
95	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 755-764.	7.1	19
96	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. Stroke, 2015, 46, 2779-2785.	2.0	19
97	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <sc>ATMOSPHERE</sc> trial. European Journal of Heart Failure, 2018, 20, 136-147.	7.1	18
98	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. Korean Circulation Journal, 2019, 49, 469.	1.9	18
99	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (â€PRESERVE) trial. European Journal of Heart Failure, 2016, 18, 1021-1031.	7.1	17
100	Heart Failure. Endocrinology and Metabolism Clinics of North America, 2018, 47, 117-135.	3.2	17
101	Body mass index and Bâ€lines on lung ultrasonography in chronic and acute heart failure. ESC Heart Failure, 2020, 7, 1201-1209.	3.1	17
102	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 2010, 12, 66-74.	7.1	16
103	Clinical characteristics and outcomes of patients with angina and heart failure in the <sc>CHARM</sc> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314.1gBT /Overclock 10	7.1	16
104	A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation?. European Stroke Journal, 2018, 3, 355-360.	5.5	16
105	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512.	1.6	16
106	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 2020, 7, 1595-1604.	3.1	15
107	Characteristic Adverse Events and Their Incidence Among Patients Participating in Acute Ischemic Stroke Trials. Stroke, 2014, 45, 2677-2682.	2.0	14
108	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq0 0 0 rgBT /Overclock 10 Tf 50 57	2.0	14

#	ARTICLE	IF	CITATIONS
109	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. Lancet Diabetes and Endocrinology, 2020, 8, 357-360.	11.4	14
110	Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group. European Stroke Journal, 2020, 5, 184-192.	5.5	13
111	Haemodynamic effects of the nitroxyl donor cimlanod (<scp>BMS</scp>â€986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 2021, 23, 1147-1155.	7.1	13
112	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. JACC: Heart Failure, 2021, 9, 386-397.	4.1	11
113	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	3.0	10
114	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	3.1	9
115	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	7.1	9
116	Paroxysmal atrial fibrillation after ischemic stroke: how should we hunt for it?. Expert Review of Cardiovascular Therapy, 2013, 11, 485-494.	1.5	8
117	Early in-hospital exposure to statins and outcome after intracerebral haemorrhage â€” Results from the Virtual International Stroke Trials Archive. European Stroke Journal, 2020, 5, 85-93.	5.5	8
118	The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: A systematic review and meta-analysis of observational studies. European Stroke Journal, 2020, 5, 155-168.	5.5	8
119	Feasibility Platform for Stroke Studies. Stroke, 2015, 46, 137-142.	2.0	7
120	Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1363-1368.	1.6	7
121	Professional guideline versus product label selection for treatment with IV thrombolysis: An analysis from SITS registry. European Stroke Journal, 2018, 3, 39-46.	5.5	7
122	Lung ultrasound: monitoring congestion in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1614-1615.	7.1	7
123	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 2019, 21, 699-702.	7.1	7
124	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke, 2020, 51, 2347-2354.	2.0	7
125	Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 2021, 8, 1784-1795.	3.1	7
126	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2021, 52, 1450-1454.	2.0	7

#	ARTICLE	IF	CITATIONS
127	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020, 5, 374-383.	5.5	6
128	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <sc>PARAGON-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 672-677.	7.1	6
129	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021, 144, e40.	1.6	6
130	Screening for atrial fibrillation after stroke or TIA. <i>Lancet Neurology</i> , The, 2015, 14, 345-347.	10.2	5
131	Are you suffering from a large arterial occlusion? Please raise your arm!. <i>Stroke and Vascular Neurology</i> , 2018, 3, 215-221.	3.3	5
132	Paired vagus nerve stimulation for treatment of upper extremity impairment after stroke. <i>International Journal of Stroke</i> , 2022, 17, 1061-1066.	5.9	5
133	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	1.4	5
134	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019, 4, 55-64.	5.5	4
135	Effects of apixaban compared with warfarin as gain in event-free time " a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	1.8	4
136	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	2.6	3
137	Zinc containing dental fixative causing copper deficiency myelopathy. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219802.	0.5	3
138	Stroke aetiological classification reliability and effect on trial sample size: systematic review, meta-analysis and statistical modelling. <i>Trials</i> , 2019, 20, 107.	1.6	3
139	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials." <i>Circulation</i> , 2015, 132, e358.	1.6	2
140	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	5.5	1
141	Online Tool to Improve Stratification of Adverse Events in Stroke Clinical Trials. <i>Stroke</i> , 2016, 47, 882-885.	2.0	1
142	The role of single pill combination therapy in the prevention of ischaemic stroke. <i>Scottish Medical Journal</i> , 2019, 64, 126-132.	1.3	1